Literature DB >> 29675373

Comparison of the effects of intravitreal bevacizumab and dexamethasone in experimental posterior penetrating eye injury.

Ayse Oner1, Nisa Kahraman1, Saim Ozdamar2, Esra Balcioglu2.   

Abstract

AIM: To compare the effects of intravitreal anti-vascular endothelial growth factor (VEGF) and dexamethasone in an experimental rabbit model of posterior penetrating ocular injury.
METHODS: Thirty white New Zealand rabbits were included in the study. A posterior penetrating ocular injury was performed at the superotemporal quadrant. They were randomly divided into three groups. The rabbits in group 1 received intravitreal dexamethasone, in group 2 they received intravitreal bevacizumab and those in group 3 received intravitreal physiological saline solution in both eyes. All eyes were examined ophthalmologically on the 1st, 3rd, 7th, 14th and 28th days following the injury and the clinical findings were scored. On the day 28, the eyes were enucleated, evaluated and scored macroscopically, histopathologically and scanning electron microscopically.
RESULTS: The median clinical score on the 14th and 28th days and the median macroscopic score of the dexamethasone group was significantly better than that of control (P=0.004, 0.018). Dexamethasone group was also better than that of bevacizumab group but the differences did not reach statistical significance. Retinal detachment rate was 8.3%, 16.6% and 12.5% in the dexamethasone group, bevacizumab group and control group, respectively (P=0.476). More extensive fibrocelluler proliferations were observed in controls compared with dexamethasone and bevacizumab groups. But these differences did not reach the statistical significance (P=0.538). In scanning electron microscopy all groups showed fibreous stalk and dense collagen fibrils in vitreous.
CONCLUSION: This study shows that intravitreal injection of both dexamethasone and bevacizumab may reduce the intraocular fibrous proliferation after an experimental posterior penetrating ocular injury in rabbits.

Entities:  

Keywords:  bevacizumab; dexamethasone; experimental; posterior penetrating ocular injury; proliferative vitreoretinopathy

Year:  2018        PMID: 29675373      PMCID: PMC5902359          DOI: 10.18240/ijo.2018.04.06

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  20 in total

1.  Experimental posterior perforating ocular injury in rabbit eyes: effects of radiotherapy with or without intravitreal cyclosporin on vitreous proliferation.

Authors:  Sarper Karakücük; Serdar Soyuer; Ayse Oztürk Oner; Isin Soyuer; Kadir Yaray; Ertugrul Mirza; Gülden Baskol; Aynur Akin
Journal:  Ophthalmologica       Date:  2006       Impact factor: 3.250

Review 2.  The Sustained-Release Dexamethasone Implant: Expanding Indications in Vitreoretinal Disease.

Authors:  K G Kapoor; M G Wagner; A L Wagner
Journal:  Semin Ophthalmol       Date:  2014-03-21       Impact factor: 1.975

3.  Therapeutic effect of periocular corticosteroids in experimental proliferative vitreoretinopathy.

Authors:  P E Rubsamen; S W Cousins
Journal:  Retina       Date:  1997       Impact factor: 4.256

4.  The role of intravitreal bevacizumab in experimental posterior penetrating eye injury.

Authors:  Morteza Mehdizadeh; Fariba Fattahi; Masoumeh Eghtedari; Mohammad H Nowroozzadeh; Foroogh Toosi
Journal:  Retina       Date:  2011-01       Impact factor: 4.256

5.  Effect of intraoperative 5-fluorouracil and low molecular weight heparin on the outcome of high-risk proliferative vitreoretinopathy.

Authors:  Sunil Ganekal; Syril Dorairaj
Journal:  Saudi J Ophthalmol       Date:  2014-03-21

Review 6.  Proliferative vitreoretinopathy: A new concept of disease pathogenesis and practical consequences.

Authors:  J Carlos Pastor; Jimena Rojas; Salvador Pastor-Idoate; Salvatore Di Lauro; Lucia Gonzalez-Buendia; Santiago Delgado-Tirado
Journal:  Prog Retin Eye Res       Date:  2015-07-21       Impact factor: 21.198

Review 7.  [Pharmacological approach to treatment of proliferative vitreoretinopathy].

Authors:  C S Priglinger; S Priglinger
Journal:  Ophthalmologe       Date:  2013-10       Impact factor: 1.059

8.  Experimental study on drug therapy of "traction retinal detachment" after posterior penetrating eye injury in the rabbit.

Authors:  W Behrens-Baumann; M Vogel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

9.  Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit.

Authors:  Farnaz Memarzadeh; Rohit Varma; Le-Tien Lin; Jignesh G Parikh; Laurie Dustin; Ana Alcaraz; Dean Eliott
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-01-31       Impact factor: 4.799

10.  Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery.

Authors:  Wendy Tseng; Rafael T Cortez; Gema Ramirez; Sandra Stinnett; Glenn J Jaffe
Journal:  Am J Ophthalmol       Date:  2004-06       Impact factor: 5.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.